Recalled Medicines & supplements – Current GIS Alerts 2026
Found 713 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
APAP dla dzieci FORTE
The suspension contains gas bubbles, is foamy and completely or almost completely fills the bottle, preventing shaking, homogenization and correct dosing of the medicinal product. Potential effects: improper dosing of paracetamol, lack of efficacy or overdose, possible adverse reactions.
APAP dla dzieci FORTE
The suspension in the bottles contained gas bubbles, was foamed, non-homogeneous and layered, and the bottles were completely or almost completely filled, which prevented shaking, homogenization and correct dosing of the medicinal product. Potential effects: incorrect paracetamol dose, lack of treatment efficacy or risk of overdose.
Tadalafil Aurovitas
The batch TGSD21011-A did not meet quality requirements due to a negative result for the parameter “release of tadalafil within 15 minutes”, which may affect treatment effectiveness. Potential effects: lack of therapeutic efficacy.
Auroverin MR
The test showed that the release of mebeverine hydrochloride was slower than allowed by quality requirements, which affects the product’s effectiveness and poses a real and direct threat to patients’ health or life. Potential effects: lack of treatment efficacy, possible worsening of symptoms, complications.
Syldenafilu cytrynian
If the description of the primary packaging of the pharmaceutical substance does not match its actual content, there is a risk of using the wrong substance in compounding a prescription medicine. An incorrect expiry date may lead to use beyond the period with guaranteed efficacy and safety. Potential effects: lack of treatment efficacy, adverse reactions, complications.
Syldenafilu cytrynian
It was found that packaging may be incorrectly labelled, including substance name, batch number and expiry date, which can lead to using the wrong raw material in compounded medicines or using it after the period guaranteeing its efficacy and safety. Potential effects: lack of treatment efficacy, adverse reactions or complications due to use of an incorrect active substance.
Autostrzykawka Morfina Przeciwko Bólowi
A problem with solution color was identified: in 4 of 92 auto-injectors the liquid was light green or green instead of colorless or pale yellow, linked to a decrease in the excipient sodium metabisulfite in batch 151021A. Potential effects: possible reduced efficacy and safety of treatment, unpredictable drug action.
Oxylaxon
A quality defect was identified involving excessively high oxycodone hydrochloride content in certain Oxylaxon prolonged-release tablet batches, caused by abnormal parameters of granulate batch EE03807. Potential effects: opioid overdose, respiratory depression, poisoning.
Oxylaxon
Failure of the medicinal products to meet the specified quality requirement manifests as excessively high content of one of the two active substances, oxycodone hydrochloride, which may expose patients to receiving a substandard medicinal product. Potential effects: excessive opioid effect, serious adverse reactions, complications of pain therapy.
Oxylaxon
The failure of the medicinal products to meet the established quality requirement manifests as an excessively high content of one of the two active substances, i.e. oxycodone hydrochloride. Potential effects: risk of overdose, poisoning, and increased opioid adverse effects.
Oxylaxon
A quality defect was identified consisting of an excessively high content of oxycodone hydrochloride in selected product batches, resulting from the use of granulate with incorrect quality parameters. Potential effects: opioid overdose, increased adverse reactions, respiratory depression, serious health complications.
Oxylaxon
In this case, the failure of the medicinal products to meet their specified quality requirement manifests as an excessively high content of one of the two active substances, i.e. oxycodone hydrochloride. Potential effects: opioid overdose, increased adverse reactions, risk to the patient’s health.
Oxylaxon
In this case, the failure of the medicinal products to meet their established quality requirement manifests as an excessively high content of one of the two active substances, i.e. oxycodone hydrochloride. Potential effects: risk of opioid overdose, increased adverse reactions, respiratory complications.
Linezolid Polpharma
Incorrect release of the active substance from the medicinal product, to an extent that may affect its therapeutic properties, constitutes a real risk to patients' health due to the potential lack of efficacy. Potential effects: ineffective treatment of infections, risk of disease progression or complications.
Benodil
The quality defect consists in labelling Benodil 0.25 mg/ml ampoules with Budixon Neb 0.5 mg/ml labels, which may mislead regarding the dose and use of the medicine. Potential effects: incorrect dosing, lack of therapeutic efficacy, or risk of complications in patients requiring an accurate corticosteroid dose.
Benodil
Failure to meet quality requirements consists in ampoules being labeled as a different medicinal product with a higher strength, which may cause dosing mix‑ups and medication errors. Potential effects: lack of treatment efficacy or complications related to incorrect dosing.
BOSS Energy, Dietary supplement
Presence of undeclared pharmacologically active substances: sildenafil and tadalafil. Unknown origin, purity and dosage. Potential effects: drug interactions, blood pressure drop, arrhythmias, serious reactions in people taking PDE5 inhibitors or nitrates.
Linezolid Polpharma
Stability testing showed non-compliance in active substance release after 30 minutes, which may affect the product’s effectiveness and poses a real risk to patient health due to potential lack of efficacy. Potential effects: treatment failure, risk of infection progression.
Benodil
there is a justified suspicion that the unit packs of the medicinal product contain a product with a significantly higher dose of active substance than indicated on the outer labelling, creating a real risk that patients will take several times the intended dose. Potential effects: overdose of inhaled medicine, increased corticosteroid side effects, complications in sensitive patients.
Temozolomide Sun
The active substance content is reduced below the lower acceptable limit specified in the product specification, which affects the medicinal product’s effectiveness. Potential effects: lack of treatment efficacy.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.